PMID- 20061691
OWN - NLM
STAT- MEDLINE
DCOM- 20100311
LR  - 20181201
IS  - 1319-2442 (Print)
IS  - 1319-2442 (Linking)
VI  - 21
IP  - 1
DP  - 2010 Jan
TI  - Profile of low molecular weight tinzaparin sodium for anticoagulation during 
      hemodialysis.
PG  - 43-9
AB  - Low-molecular-weight heparin (LMWH) has been suggested as providing safe, 
      efficient, convenient, and possibly more cost-effective anticoagulation for 
      hemodialysis (HD) than unfractionated heparin (UFH) with a single bolus dose at 
      the start of hemodialysis effectively prevents clot formation in the dialyzer and 
      bubble trap with fewer side-effects and possible benefits on uremic dyslipidemia. 
      In this study, we compared the safety, clinical efficacy, and cost effectiveness 
      of tinzaparin sodium (Innohep) with unfractionated heparin (UFH) in 23 chronic HD 
      patients; their extracorporeal anticoagulant protocol consisted of UFH was 
      switched to tinzaparin for a period of 6 months. Clinical clotting (grade 1-4) 
      was evaluated by visual inspection after blood draining of the air trap every 
      hour and the dialyzer after each session. Anticoagulation with tinzaparin sodium 
      resulted in less frequent dialyzer and air-trap clotting compared to UFH (P= 001 
      and 0.04 respectively). Over 24 weeks, we observed no alteration in the serum 
      lipid profile of the patients. There was a statistically significant improvement 
      in the dialysis single pool Kt/V after 6 months of tinzaparin use (1.40 + or - 
      0.28 for tinzaparin versus 1.23 + or - 0.28 for heparin) without any modification 
      in the hemodialysis prescription. The total cost for 24 weeks use of tinzaparin 
      sodium was 23% more expensive compared to that for UFH. We conclude that a single 
      bolus of Tinzaparin sodium injection at the start of the dialysis session was 
      more effective and convenient in our patients than UFH, but at a higher total 
      cost. Furthermore, at least on the short term, there was no observed benefit on 
      the lipid profile.
FAU - Al-Saran, Khalid A
AU  - Al-Saran KA
AD  - Prince Salman Center for Kidney Disease, Riyadh, Saudi Arabia. 
      khalid_aln@yahoo.co.uk
FAU - Sabry, Alaa
AU  - Sabry A
FAU - Taha, Moammer
AU  - Taha M
FAU - Ghafour, Mamdouh Abdul
AU  - Ghafour MA
FAU - Al Fawzan, Fawzan
AU  - Al Fawzan F
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Saudi Arabia
TA  - Saudi J Kidney Dis Transpl
JT  - Saudi journal of kidney diseases and transplantation : an official publication of 
      the Saudi Center for Organ Transplantation, Saudi Arabia
JID - 9436968
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 7UQ7X4Y489 (Tinzaparin)
SB  - IM
MH  - Adult
MH  - Anticoagulants/*administration & dosage/adverse effects/economics
MH  - Blood Coagulation/*drug effects
MH  - Cost-Benefit Analysis
MH  - Drug Costs
MH  - Female
MH  - Heparin, Low-Molecular-Weight/*administration & dosage/adverse effects/economics
MH  - Humans
MH  - Injections
MH  - Male
MH  - Middle Aged
MH  - *Renal Dialysis/adverse effects/economics
MH  - Thrombosis/blood/economics/etiology/*prevention & control
MH  - Time Factors
MH  - Tinzaparin
EDAT- 2010/01/12 06:00
MHDA- 2010/03/12 06:00
CRDT- 2010/01/12 06:00
PHST- 2010/01/12 06:00 [entrez]
PHST- 2010/01/12 06:00 [pubmed]
PHST- 2010/03/12 06:00 [medline]
AID - SaudiJKidneyDisTranspl_2010_21_1_43_58706 [pii]
PST - ppublish
SO  - Saudi J Kidney Dis Transpl. 2010 Jan;21(1):43-9.